Zobrazeno 1 - 10
of 220
pro vyhledávání: '"Kw, Wucherpfennig"'
Autor:
Rh, Vonderheide, Joachim Schultze, Ks, Anderson, Maecker B, Mo, Butler, Xia Z, Mj, Kuroda, Ms, Bergwelt-Baildon, Mm, Bedor, Km, Hoar, Dr, Schnipper, Mw, Brooks, Nl, Letvin, Kf, Stephans, Kw, Wucherpfennig, Wc, Hahn, Lm, Nadler
Publikováno v:
Europe PubMed Central
Although high frequencies of T lymphocytes specific for certain tumor-associated antigens have been detected in some cancer patients, increasing evidence suggests that these T cells may be functionally defective in vivo and fail to induce meaningful
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6ecdc8c5d124f04025f04996f7816f34
https://pubmed.ncbi.nlm.nih.gov/11731409
https://pubmed.ncbi.nlm.nih.gov/11731409
Autor:
Zhao Y; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Immunology, Harvard Medical School, Boston, Massachusetts.; Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Dec 16; Vol. 30 (24), pp. 5527-5534.
Autor:
Iwamoto FM; Columbia University, New York, NY, United States., Tanguturi SK; Brigham and Women's Hospital, Boston, Massachusetts, United States., Nayak L; Center of Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, United States., Wang TJ; Columbia University Medical Center, New York, New York, United States., Desai A; University of Pennsylvania, Philadelphia, PA, United States., Lustig RA; University of Pennsylvania, Philadelphia, PA, United States., Bagley S; University of Pennsylvania, Philadelphia, Pa, United States., Wong ET; Beth Israel Deaconess Med Ctr, Boston, MA, United States., Hertan LM; Beth Israel Deaconess Medical Center, Boston, MA, United States., McCluskey C; Dana-Farber Cancer Institute, Boston, MA, United States., Hayden J; Massachusetts General Hospital, Boston, MA, United States., Muzikansky A; Massachusetts General Hospital, Boston, MA, United States., Nakhawa S; Dana-Farber Cancer Institute, Boston, MA, United States., Japo J; Dana-Farber Cancer Institute, United States., Bossi CC; Dana-Farber Cancer Institute., Meylan M; Centre de Recherche des Cordeliers, Inserm UMRS 1138, Paris, France., Tian Y; Dana-Farber Cancer Institute, United States., Barlow GL; Dana-Farber Cancer Institute, United States., Speliakos P; Dana-Farber Cancer Institute, United States., Ayoub G; Dana-Farber Cancer Institute, Boston, United States., Meredith DM; Dana-Farber Cancer Institute, United States., Ligon KL; Dana-Farber Cancer Institute, Boston, MA, United States., Haas-Kogan D; Dana-Farber Cancer Institute, Boston, MA, United States., Huang K; Dana-Farber/Brigham and Women's Cancer Center, United States., Wucherpfennig KW; Dana-Farber Cancer Institute, Boston, MA, United States., Wen PY; Dana-Farber Cancer Institute, Boston, MA, United States., Reardon DA; Dana-Farber Cancer Institute, Boston, MA, United States.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Nov 08. Date of Electronic Publication: 2024 Nov 08.
Autor:
Tahri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Piccinelli S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA., Su NK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Lampe L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA.; Medical Department, Christian-Albrechts University, Kiel, Germany., Dong H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Vergara Cadavid J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Boiarsky R; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA., Papazian N; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Lightbody ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Cao A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA., Alberge JB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Ferrari de Andrade L; Precision Immunology Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai Hospital, New York, NY., Rahmat M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Shen Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Cancer Science Institute of Singapore, National University of Singapore Cancer Science, Singapore, Singapore.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Blanco Fernández L; Clínica Universidad de Navarra, Center for Applied Medical Research, CIBERONC, IDISNA, Pamplona, Spain., Zabaleta A; Clínica Universidad de Navarra, Center for Applied Medical Research, CIBERONC, IDISNA, Pamplona, Spain., Günther A; Medical Department, Christian-Albrechts University, Kiel, Germany., Getz G; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Krantz Family Center for Cancer Research and Deptartment of Pathology, Massachusetts General Hospital, Boston, MA.; Department of Pathology, Harvard Medical School, Boston, MA., Sonneveld P; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Cupedo T; Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA.; Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA., Romee R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Department of Medical Oncology, Harvard Medical School, Boston, MA.
Publikováno v:
Blood advances [Blood Adv] 2024 Oct 22; Vol. 8 (20), pp. 5365-5370.
Autor:
Rakhshandehroo T; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Mantri SR; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Moravej H; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Louis BBV; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Salehi Farid A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Munaretto L; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Regan K; Department of Biomedical Engineering, Boston University, Boston, MA, USA., Khan RMM; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Wolff A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Farkash Z; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Cong M; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Kuhnast A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Nili A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Lee UJ; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Allen HH; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Berland L; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Simkova E; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Uslu SC; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Tavakolpour S; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Rowley JE; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biomedical Engineering, Boston University, Boston, MA, USA., Codet E; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Shahbazian H; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Baral J; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Pyrdol J; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA., Jacobson CA; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nadeem O; Harvard Medical School, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Nia HT; Department of Biomedical Engineering, Boston University, Boston, MA, USA., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA., Rashidian M; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA. Mohammad_rashidian@dfci.harvard.edu.; Harvard Medical School, Boston, MA, USA. Mohammad_rashidian@dfci.harvard.edu.; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Mohammad_rashidian@dfci.harvard.edu.; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Mohammad_rashidian@dfci.harvard.edu.
Publikováno v:
Nature biotechnology [Nat Biotechnol] 2024 Jul 30. Date of Electronic Publication: 2024 Jul 30.
Autor:
Zhao Y; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute.; Department of Immunology, Harvard Medical School.; Department of Neurology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
Publikováno v:
Current opinion in oncology [Curr Opin Oncol] 2024 May 01; Vol. 36 (3), pp. 136-142. Date of Electronic Publication: 2024 Feb 07.
Autor:
Janiszewska M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Department of Molecular Medicine, The Scripps Research Institute, Jupiter, FL, USA., Tabassum DP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Research Square, Durham, NC, USA., Castaño Z; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Cristea S; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA., Yamamoto KN; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA., Kingston NL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Murphy KC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Shu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Harper NW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Del Alcazar CG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Alečković M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Ekram MB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; WuXi NextCODE, Cambridge, MA, USA., Cohen O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA., Kwak M; Department of Biomedical Engineering, Yale School of Medicine, New Haven, CT, USA.; Yale Comprehensive Cancer Center, New Haven, CT, USA., Qin Y; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; EdiGene, Cambridge, MA, USA., Laszewski T; Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Luoma A; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, and Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA., Marusyk A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Department of Cancer Imaging and Metabolism, Moffitt Cancer Center, Tampa, FL, USA., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, and Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA, USA., Wagle N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA., Fan R; Department of Biomedical Engineering, Yale School of Medicine, New Haven, CT, USA.; Yale Comprehensive Cancer Center, New Haven, CT, USA., Michor F; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA, USA.; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA, USA.; The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA.; Ludwig Center at Harvard, Boston, MA, USA., McAllister SS; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Hematology Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Harvard Stem Cell Institute, Cambridge, MA, USA., Polyak K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. kornelia_polyak@dfci.harvard.edu.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. kornelia_polyak@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. kornelia_polyak@dfci.harvard.edu.; The Eli and Edythe L. Broad Institute of Harvard and MIT, Cambridge, MA, USA. kornelia_polyak@dfci.harvard.edu.; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA, USA. kornelia_polyak@dfci.harvard.edu.; Ludwig Center at Harvard, Boston, MA, USA. kornelia_polyak@dfci.harvard.edu.; Harvard Stem Cell Institute, Cambridge, MA, USA. kornelia_polyak@dfci.harvard.edu.
Publikováno v:
Nature cell biology [Nat Cell Biol] 2024 May; Vol. 26 (5), pp. 841.
Autor:
Alvarez Calderon F; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA.; Harvard Medical School, Boston, MA., Kang BH; Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA., Kyrysyuk O; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Zheng S; Department of Genetics and Genomic Sciences, Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY., Wang H; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Immunology, Harvard Medical School, Boston, MA., Mathewson ND; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Immunology, Harvard Medical School, Boston, MA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA., Luoma AM; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Immunology, Harvard Medical School, Boston, MA., Ning X; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Department of Immunology, Harvard Medical School, Boston, MA., Pyrdol J; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Cao X; Department of Genetics and Genomic Sciences, Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY., Suvà ML; Department of Pathology and Center for Cancer Research, Massachusetts General Hospital, Boston, MA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA., Yuan GC; Department of Genetics and Genomic Sciences, Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY., Wittrup KD; Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA.; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; Harvard Medical School, Boston, MA.; Department of Immunology, Harvard Medical School, Boston, MA.; Department of Neurology, Brigham and Women's Hospital, Boston, MA.
Publikováno v:
Blood [Blood] 2024 Mar 21; Vol. 143 (12), pp. 1124-1138.
Autor:
Verhaar ER; Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.; Department of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, Netherlands., Knoflook A; Boston Children's Hospital, Harvard Medical School, Boston, MA, United States., Pishesha N; Division of Immunology, Boston Children's Hospital, Boston, MA, United States.; Department of Pediatrics, Harvard Medical School, Boston, MA, United States., Liu X; Boston Children's Hospital, Harvard Medical School, Boston, MA, United States., van Keizerswaard WJC; Boston Children's Hospital, Harvard Medical School, Boston, MA, United States., Wucherpfennig KW; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, United States., Ploegh HL; Boston Children's Hospital, Harvard Medical School, Boston, MA, United States.; Department of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, Netherlands.
Publikováno v:
Frontiers in immunology [Front Immunol] 2024 Mar 14; Vol. 15, pp. 1368586. Date of Electronic Publication: 2024 Mar 14 (Print Publication: 2024).
Autor:
Jovanović B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Temko D; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA., Stevens LE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Seehawer M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Fassl A; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA., Murphy K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Anand J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Garza K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gulvady A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Qiu X; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Harper NW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Daniels VW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Xiao-Yun H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ge JY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, MA 02115, USA., Alečković M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Pyrdol J; Departments of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Departments of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA., Hinohara K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Egri SB; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA., Papanastasiou M; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA., Vadhi R; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Font-Tello A; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Witwicki R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Peluffo G; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Trinh A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Shu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Diciaccio B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ekram MB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Subedee A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Herbert ZT; Department of Molecular Biology Core Facility, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Wucherpfennig KW; Departments of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Departments of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA., Letai AG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA., Jaffe JD; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA., Sicinski P; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA., Brown M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA., Dillon D; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA., Long HW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Michor F; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: michor@jimmy.harvard.edu., Polyak K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA; Center for Cancer Evolution, Dana-Farber Cancer Institute, Boston, MA 02215, USA. Electronic address: kornelia_polyak@dfci.harvard.edu.
Publikováno v:
Cell reports [Cell Rep] 2023 Dec 26; Vol. 42 (12), pp. 113564. Date of Electronic Publication: 2023 Dec 14.